{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:57:50Z","timestamp":1791237470349,"version":"4.1.0"},"reference-count":96,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2025,1,1]]},"abstract":"<jats:sec id=\"ab-nrv240006-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>\n                      Advancements in molecular engineering have facilitated the creation of engineered T cells that express synthetic receptors, termed\n                      <jats:italic>chimeric antigen receptors<\/jats:italic>\n                      (CARs). This is promising not only in cancer treatment but also in addressing a spectrum of other conditions. This review provides a comprehensive overview of the current approaches and future potential of CAR T-cell therapy in the field of neurology, particularly for primary brain tumors and autoimmune neurological disorders.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-nrv240006-2\">\n                    <jats:title>Observations<\/jats:title>\n                    <jats:p>\n                      CAR T-cell therapy for glioblastoma is promising; however, first-in-human trials did not yield significant success or showed only limited success in a subset of patients. To date, the efficacy of CAR T-cell therapies has been demonstrated in animal models of multiple sclerosis, but larger human studies to corroborate the efficacy remain pending. CAR T cells showed efficacy in treatment of patients with relapsed or refractory aquaporin 4\u2013immunoglobulin G\u2013seropositive neuromyelitis optica spectrum disorders. Further studies with larger patient populations are needed to confirm these results. Success was reported also for treatment of cases with generalized myasthenia gravis using CAR T cells. Chimeric autoantibody receptor T cells, representing a modified form of CAR T cells directed against autoreactive B cells secreting autoantibodies, were used to selectively target autoreactive anti\u2013\n                      <jats:italic>N<\/jats:italic>\n                      -methyl-\n                      <jats:sc>d<\/jats:sc>\n                      -aspartate B cells under in vitro and in vivo conditions, providing the basis for human studies and application to other types of autoimmune encephalitis associated with neuronal or glial antibodies.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-nrv240006-3\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>CAR T cells herald a new era in the therapeutic landscape of neurological disorders. While their application in solid tumors, such as glioblastoma, has not universally yielded robust success, emerging innovative strategies show promise, and there is optimism for their effectiveness in certain autoimmune neurological disorders.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaneurol.2024.3818","type":"journal-article","created":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T11:32:23Z","timestamp":1732534343000},"page":"93","source":"Crossref","is-referenced-by-count":41,"title":["Current and Future Roles of Chimeric Antigen Receptor T-Cell Therapy in Neurology"],"prefix":"10.1001","volume":"82","author":[{"given":"Fatme Seval","family":"Ismail","sequence":"first","affiliation":[{"name":"Department of Neurology, Klinikum Vest, Academic Teaching Hospital of the Ruhr University Bochum, Recklinghausen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Gallus","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, University of California, San Francisco"},{"name":"Department of Neurosurgery, University Hospital Muenster, Muenster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven G.","family":"Meuth","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical Faculty and University Hospital, Heinrich-Heine University of D\u00fcsseldorf, D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideho","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, University of California, San Francisco"},{"name":"Parker Institute for Cancer Immunotherapy, San Francisco, California"},{"name":"Helen Diller Family Comprehensive Cancer Center, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Hartung","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical Faculty and University Hospital, Heinrich-Heine University of D\u00fcsseldorf, D\u00fcsseldorf, Germany"},{"name":"Brain and Mind Center, University of Sydney, Sydney, New South Wales, Australia"},{"name":"Department of Neurology, Palacky University Olomouc, Olomouc, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nico","family":"Melzer","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical Faculty and University Hospital, Heinrich-Heine University of D\u00fcsseldorf, D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"nrv240006r1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrneurol.2017.148","article-title":"Antisense oligonucleotides: the next frontier for treatment of neurological disorders.","volume":"14","author":"Rinaldi","year":"2018","journal-title":"Nat Rev Neurol"},{"issue":"6629","key":"nrv240006r2","doi-asserted-by":"publisher","DOI":"10.1126\/science.add8643","article-title":"CRISPR technology: a decade of genome editing is only the beginning.","volume":"379","author":"Wang","year":"2023","journal-title":"Science"},{"issue":"1","key":"nrv240006r3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle.","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"issue":"5256","key":"nrv240006r4","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade.","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"issue":"11","key":"nrv240006r5","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J"},{"issue":"10304","key":"nrv240006r6","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma.","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"issue":"21","key":"nrv240006r7","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1056\/NEJMoa020586","article-title":"A controlled trial of a human papillomavirus type 16 vaccine.","volume":"347","author":"Koutsky","year":"2002","journal-title":"N Engl J Med"},{"issue":"5","key":"nrv240006r8","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1470-2045(05)70101-7","article-title":"Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial.","volume":"6","author":"Villa","year":"2005","journal-title":"Lancet Oncol"},{"issue":"5","key":"nrv240006r9","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine.","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"issue":"27","key":"nrv240006r10","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine.","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"nrv240006r11","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines\u2014a new era in vaccinology.","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"nrv240006r12","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1182\/blood-2007-12-128843","article-title":"Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.","volume":"112","author":"Till","year":"2008","journal-title":"Blood"},{"issue":"20","key":"nrv240006r13","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","article-title":"Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood"},{"issue":"8","key":"nrv240006r14","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"issue":"16","key":"nrv240006r15","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"issue":"6165","key":"nrv240006r16","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1126\/science.342.6165.1432","article-title":"Breakthrough of the year 2013: cancer immunotherapy.","volume":"342","author":"Couzin-Frankel","year":"2013","journal-title":"Science"},{"issue":"1","key":"nrv240006r17","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy.","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"issue":"7971","key":"nrv240006r18","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/s41586-023-06243-w","article-title":"CAR T therapy beyond cancer: the evolution of a living drug.","volume":"619","author":"Baker","year":"2023","journal-title":"Nature"},{"issue":"4","key":"nrv240006r19","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/s41591-022-01765-8","article-title":"Engineered cellular immunotherapies in cancer and beyond.","volume":"28","author":"Finck","year":"2022","journal-title":"Nat Med"},{"issue":"4","key":"nrv240006r20","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002907","article-title":"CAR T cells for treating autoimmune diseases.","volume":"9","author":"Blache","year":"2023","journal-title":"RMD Open"},{"issue":"26","key":"nrv240006r21","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor T-cell therapy.","volume":"375","author":"Brown","year":"2016","journal-title":"N Engl J Med"},{"issue":"399","key":"nrv240006r22","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa0984","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.","volume":"9","author":"O\u2019Rourke","year":"2017","journal-title":"Sci Transl Med"},{"issue":"8","key":"nrv240006r23","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1001\/jamaoncol.2017.0184","article-title":"HER2-specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial.","volume":"3","author":"Ahmed","year":"2017","journal-title":"JAMA Oncol"},{"issue":"7903","key":"nrv240006r24","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","article-title":"GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas.","volume":"603","author":"Majzner","year":"2022","journal-title":"Nature"},{"issue":"18","key":"nrv240006r25","doi-asserted-by":"publisher","first-page":"4062","DOI":"10.1158\/1078-0432.CCR-15-0428","article-title":"Bioactivity and safety of IL13Ra2-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma.","volume":"21","author":"Brown","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"4","key":"nrv240006r26","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/s41591-024-02875-1","article-title":"Locoregional delivery of IL-13Ra2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial.","volume":"30","author":"Brown","year":"2024","journal-title":"Nat Med"},{"issue":"8","key":"nrv240006r27","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1093\/neuonc\/noac024","article-title":"Off-the-shelf, steroid-resistant, IL13Ra2-specific CAR T cells for treatment of glioblastoma.","volume":"24","author":"Brown","year":"2022","journal-title":"Neuro Oncol"},{"issue":"4","key":"nrv240006r28","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/CJI.0000000000000260","article-title":"Pilot trial of adoptive transfer of chimeric antigen receptor-transduced T cells targeting EGFRvIII in patients with glioblastoma.","volume":"42","author":"Goff","year":"2019","journal-title":"J Immunother"},{"issue":"14","key":"nrv240006r29","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","article-title":"Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma.","volume":"390","author":"Choi","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"nrv240006r30","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1038\/s41591-024-02893-z","article-title":"Intrathecal bivalent CAR T cells targeting EGFR and IL13Ra2 in recurrent glioblastoma: phase 1 trial interim results.","volume":"30","author":"Bagley","year":"2024","journal-title":"Nat Med"},{"issue":"6","key":"nrv240006r31","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.medj.2024.03.002","article-title":"CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis.","volume":"5","author":"Fischbach","year":"2024","journal-title":"Med"},{"issue":"12","key":"nrv240006r32","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/S1474-4422(23)00375-7","article-title":"Anti-CD19 CAR T cells for refractory myasthenia gravis.","volume":"22","author":"Haghikia","year":"2023","journal-title":"Lancet Neurol"},{"issue":"26","key":"nrv240006r33","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2403227121","article-title":"Successful use of anti-CD19 CAR T cells in severe treatment-refractory stiff-person syndrome.","volume":"121","author":"Faissner","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"nrv240006r34","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41392-022-01278-3","article-title":"Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results.","volume":"8","author":"Qin","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"nrv240006r35","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","article-title":"Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study.","volume":"22","author":"Granit","year":"2023","journal-title":"Lancet Neurol"},{"issue":"11","key":"nrv240006r36","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1016\/j.neuron.2024.04.014","article-title":"Treatment of concomitant myasthenia gravis and Lambert-Eaton myasthenic syndrome with autologous CD19-targeted CAR T cells.","volume":"112","author":"Motte","year":"2024","journal-title":"Neuron"},{"key":"nrv240006r37","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.694941","article-title":"First-in-human trial of EphA2-redirected CAR T-cells in patients with recurrent glioblastoma: a preliminary report of three cases at the starting dose.","volume":"11","author":"Lin","year":"2021","journal-title":"Front Oncol"},{"issue":"1","key":"nrv240006r38","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12943-022-01711-9","article-title":"Safety and antitumor activity of GD2-specific 4SCAR-T cells in patients with glioblastoma.","volume":"22","author":"Liu","year":"2023","journal-title":"Mol Cancer"},{"issue":"5","key":"nrv240006r39","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200292","article-title":"CD19-directed CAR T-cells in a patient with refractory MOGAD: clinical and immunologic follow-up for 1 year.","volume":"11","author":"Cabrera-Maqueda","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"8","key":"nrv240006r40","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1093\/neuonc\/noaa106","article-title":"Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.","volume":"22","author":"Wen","year":"2020","journal-title":"Neuro Oncol"},{"key":"nrv240006r41","doi-asserted-by":"publisher","first-page":"vii17","DOI":"10.1093\/neuonc\/noy158","article-title":"Updates in prognostic markers for gliomas.","volume":"20","author":"Aquilanti","year":"2018","journal-title":"Neuro Oncol"},{"issue":"10","key":"nrv240006r42","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma.","volume":"352","author":"Hegi","year":"2005","journal-title":"N Engl J Med"},{"issue":"5","key":"nrv240006r43","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1212\/WNL.0000000000012193","article-title":"Chimeric antigen receptor T cells for glioblastoma: current concepts, challenges, and future perspectives.","volume":"97","author":"Karschnia","year":"2021","journal-title":"Neurology"},{"key":"nrv240006r44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.817296","article-title":"CAR T cell therapy in primary brain tumors: current investigations and the future.","volume":"13","author":"Lin","year":"2022","journal-title":"Front Immunol"},{"issue":"9","key":"nrv240006r45","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1038\/s41591-021-01404-8","article-title":"Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis.","volume":"27","author":"Vitanza","year":"2021","journal-title":"Nat Med"},{"issue":"9566","key":"nrv240006r46","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/S0140-6736(07)60461-9","article-title":"The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial.","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"issue":"6","key":"nrv240006r47","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1080\/14712598.2020.1727436","article-title":"CAR T cells and checkpoint inhibition for the treatment of glioblastoma.","volume":"20","author":"Shen","year":"2020","journal-title":"Expert Opin Biol Ther"},{"issue":"5","key":"nrv240006r48","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200139","article-title":"Synthetic cell-based immunotherapies for neurologic diseases.","volume":"10","author":"von Baumgarten","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"13","key":"nrv240006r49","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.3390\/cells12131770","article-title":"Chimeric antigen receptor T cells in glioblastoma\u2014current concepts and promising future.","volume":"12","author":"Kringel","year":"2023","journal-title":"Cells"},{"issue":"1","key":"nrv240006r50","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ymthe.2017.10.002","article-title":"Optimization of IL13Ra2-targeted chimeric antigen receptor T cells for improved anti-tumor efficacy against glioblastoma.","volume":"26","author":"Brown","year":"2018","journal-title":"Mol Ther"},{"issue":"10","key":"nrv240006r51","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.99048","article-title":"Glioblastoma-targeted CD4+ CAR T cells mediate superior antitumor activity.","volume":"3","author":"Wang","year":"2018","journal-title":"JCI Insight"},{"issue":"1","key":"nrv240006r52","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","article-title":"Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours.","volume":"20","author":"Flugel","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"nrv240006r53","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.cell.2016.09.011","article-title":"Engineering T cells with customized therapeutic response programs using synthetic notch receptors.","volume":"167","author":"Roybal","year":"2016","journal-title":"Cell"},{"issue":"591","key":"nrv240006r54","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abe7378","article-title":"SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma.","volume":"13","author":"Choe","year":"2021","journal-title":"Sci Transl Med"},{"issue":"7","key":"nrv240006r56","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.cell.2023.03.008","article-title":"Multiple sclerosis: neuroimmune crosstalk and therapeutic targeting.","volume":"186","author":"Charabati","year":"2023","journal-title":"Cell"},{"issue":"12","key":"nrv240006r57","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/s41577-022-00718-z","article-title":"The immunology of multiple sclerosis.","volume":"22","author":"Attfield","year":"2022","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"nrv240006r58","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.neuron.2018.01.021","article-title":"Multiple sclerosis: mechanisms and immunotherapy.","volume":"97","author":"Baecher-Allan","year":"2018","journal-title":"Neuron"},{"issue":"6","key":"nrv240006r59","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S1474-4422(24)00140-6","article-title":"B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases.","volume":"23","author":"Haghikia","year":"2024","journal-title":"Lancet Neurol"},{"issue":"8","key":"nrv240006r60","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/s41577-021-00652-6","article-title":"B cells in central nervous system disease: diversity, locations and pathophysiology.","volume":"22","author":"Jain","year":"2022","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"nrv240006r61","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/ana.25119","article-title":"B-cell therapy for multiple sclerosis: entering an era.","volume":"83","author":"Greenfield","year":"2018","journal-title":"Ann Neurol"},{"issue":"6","key":"nrv240006r62","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1093\/brain\/awab093","article-title":"Formation and immunomodulatory function of meningeal B cell aggregates in progressive CNS autoimmunity.","volume":"144","author":"Mitsdoerffer","year":"2021","journal-title":"Brain"},{"key":"nrv240006r63","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/1742-2094-9-112","article-title":"CAR\/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery.","volume":"9","author":"Fransson","year":"2012","journal-title":"J Neuroinflammation"},{"key":"nrv240006r64","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2020.104222","article-title":"Engineered regulatory T cells expressing myelin-specific chimeric antigen receptors suppress EAE progression.","volume":"358","author":"De Paula Pohl","year":"2020","journal-title":"Cell Immunol"},{"issue":"2","key":"nrv240006r65","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200080","article-title":"CAR-T cell-mediated B-cell depletion in central nervous system autoimmunity.","volume":"10","author":"Gupta","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"76","key":"nrv240006r66","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abo0777","article-title":"Antigen-specific depletion of CD4+ T cells by CAR T cells reveals distinct roles of higher- and lower-affinity TCRs during autoimmunity.","volume":"7","author":"Yi","year":"2022","journal-title":"Sci Immunol"},{"issue":"2","key":"nrv240006r67","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41591-019-0737-3","article-title":"Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma.","volume":"26","author":"Brudno","year":"2020","journal-title":"Nat Med"},{"issue":"8","key":"nrv240006r68","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s40263-022-00939-9","article-title":"Efficacy and safety of multiple sclerosis drugs approved since 2018 and future developments.","volume":"36","author":"Faissner","year":"2022","journal-title":"CNS Drugs"},{"issue":"3","key":"nrv240006r69","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s40263-018-0488-6","article-title":"Efficacy and safety of the newer multiple sclerosis drugs approved since 2010.","volume":"32","author":"Faissner","year":"2018","journal-title":"CNS Drugs"},{"issue":"1","key":"nrv240006r70","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s12185-020-02840-x","article-title":"Progressive multifocal leukoencephalopathy after CAR T therapy.","volume":"112","author":"Sdrimas","year":"2020","journal-title":"Int J Hematol"},{"issue":"5","key":"nrv240006r71","doi-asserted-by":"publisher","first-page":"212","DOI":"10.14740\/jh903","article-title":"Progressive multifocal leukoencephalopathy after chimeric antigen receptor T-cell therapy for recurrent non-Hodgkin lymphoma.","volume":"10","author":"Ahrendsen","year":"2021","journal-title":"J Hematol"},{"issue":"6","key":"nrv240006r72","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1182\/blood.2022017386","article-title":"Progressive multifocal leukoencephalopathy in patients treated with chimeric antigen receptor T cells.","volume":"141","author":"Goldman","year":"2023","journal-title":"Blood"},{"issue":"2","key":"nrv240006r73","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1093\/jnen\/nlac121","article-title":"Multifocal demyelinating leukoencephalopathy and oligodendroglial lineage cell loss with immune effector cell-associated neurotoxicity syndrome (ICANS) following CD19 CAR T-cell therapy for mantle cell lymphoma.","volume":"82","author":"Nie","year":"2023","journal-title":"J Neuropathol Exp Neurol"},{"issue":"4","key":"nrv240006r74","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1111\/ejh.13583","article-title":"Late occurrence of progressive multifocal leukoencephalopathy after anti-CD19 chimeric antigen receptor T-cell therapy.","volume":"106","author":"Mian","year":"2021","journal-title":"Eur J Haematol"},{"issue":"12","key":"nrv240006r75","doi-asserted-by":"publisher","first-page":"e870","DOI":"10.1016\/S2352-3026(21)00316-1","article-title":"Progressive multifocal leukoencephalopathy in the era of chimeric antigen receptor T-cell therapy.","volume":"8","author":"Mackenzie","year":"2021","journal-title":"Lancet Haematol"},{"issue":"4","key":"nrv240006r76","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(10)70040-5","article-title":"Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis.","volume":"9","author":"Tan","year":"2010","journal-title":"Lancet Neurol"},{"key":"nrv240006r77","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.msard.2018.12.002","article-title":"Neuromyelitis optica spectrum disorder: pathogenesis, treatment, and experimental models.","volume":"27","author":"Wu","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"8","key":"nrv240006r78","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1172\/JCI134816","article-title":"Astrocyte-microglia interaction drives evolving neuromyelitis optica lesion.","volume":"130","author":"Chen","year":"2020","journal-title":"J Clin Invest"},{"issue":"4","key":"nrv240006r79","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000110","article-title":"Aquaporin-4 autoimmunity.","volume":"2","author":"Zekeridou","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"9451","key":"nrv240006r80","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis.","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"issue":"4","key":"nrv240006r81","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel.","volume":"202","author":"Lennon","year":"2005","journal-title":"J Exp Med"},{"issue":"5","key":"nrv240006r82","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic\u2019s syndrome).","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology"},{"issue":"95","key":"nrv240006r83","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adj9730","article-title":"Single-cell analysis of anti-BCMA CAR T cell therapy in patients with central nervous system autoimmunity.","volume":"9","author":"Qin","year":"2024","journal-title":"Sci Immunol"},{"issue":"2","key":"nrv240006r84","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1152\/physrev.00010.2016","article-title":"Autoantibodies to synaptic receptors and neuronal cell surface proteins in autoimmune diseases of the central nervous system.","volume":"97","author":"Dalmau","year":"2017","journal-title":"Physiol Rev"},{"issue":"9","key":"nrv240006r85","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1056\/NEJMra1708712","article-title":"Antibody-mediated encephalitis.","volume":"378","author":"Dalmau","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"nrv240006r86","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","article-title":"A clinical approach to diagnosis of autoimmune encephalitis.","volume":"15","author":"Graus","year":"2016","journal-title":"Lancet Neurol"},{"issue":"9","key":"nrv240006r87","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/s41582-020-0381-z","article-title":"The B cell immunobiology that underlies CNS autoantibody-mediated diseases.","volume":"16","author":"Sun","year":"2020","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"nrv240006r88","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001014","article-title":"Updated diagnostic criteria for paraneoplastic neurologic syndromes.","volume":"8","author":"Graus","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"12","key":"nrv240006r89","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S1474-4422(08)70224-2","article-title":"Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies.","volume":"7","author":"Dalmau","year":"2008","journal-title":"Lancet Neurol"},{"issue":"23","key":"nrv240006r90","doi-asserted-by":"publisher","first-page":"5084","DOI":"10.1016\/j.cell.2023.10.001","article-title":"Chimeric autoantibody receptor T cells deplete NMDA receptor-specific B cells.","volume":"186","author":"Reincke","year":"2023","journal-title":"Cell"},{"issue":"26","key":"nrv240006r91","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia gravis.","volume":"375","author":"Gilhus","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"nrv240006r92","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S1474-4422(21)00463-4","article-title":"Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders.","volume":"21","author":"Verschuuren","year":"2022","journal-title":"Lancet Neurol"},{"issue":"4","key":"nrv240006r93","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s40265-019-1065-0","article-title":"Therapies directed against B-cells and downstream effectors in generalized autoimmune myasthenia gravis: current status.","volume":"79","author":"Beecher","year":"2019","journal-title":"Drugs"},{"issue":"9","key":"nrv240006r94","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1038\/s41587-022-01637-z","article-title":"Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells.","volume":"41","author":"Oh","year":"2023","journal-title":"Nat Biotechnol"},{"issue":"7","key":"nrv240006r95","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S1474-4422(23)00211-9","article-title":"Are CAR T cells the answer to myasthenia gravis therapy?","volume":"22","author":"Meisel","year":"2023","journal-title":"Lancet Neurol"},{"issue":"7","key":"nrv240006r96","doi-asserted-by":"publisher","first-page":"4655","DOI":"10.1007\/s00415-024-12367-4","article-title":"Bispecific BCMA\/CD19 targeted CAR-T cell therapy forces sustained disappearance of symptoms and anti-acetylcholine receptor antibodies in refractory myasthenia gravis: a case report.","volume":"271","author":"Zhang","year":"2024","journal-title":"J Neurol"},{"key":"nrv240006r55","unstructured":"Anti-EGFRvIII synNotch receptor induced anti-EphA2\/IL-13Ralpha2 CAR (E-SYNC) T cells. ClinicalTrials.gov identifier: NCT06186401. Updated July 3, 2024. Accessed October 14, 2024. https:\/\/clinicaltrials.gov\/study\/NCT06186401"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2827123\/jamaneurology_ismail_2024_rv_240006_1735932274.28162.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T11:02:07Z","timestamp":1736766127000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2827123"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2025,1,1]]},"references-count":96,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2024.3818","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,1]]}}}